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Introduction
Kidney fibrosis (chronic kidney disease, CKD) is common and confers a remarkably high morbidity and 
mortality. It can result from a variety of  injuries and diseases, very commonly diabetes and hypertension. 
Acute kidney injury (AKI) occurs in up to 10%–20% of  adult patients hospitalized with acute illness, is 
associated with significant mortality (15%–30%; up to 70% if  multiorgan failure in ICU patients), and 
causes progressive kidney fibrosis in survivors (1, 2). Regardless of  the initial insult, CKD is characterized 
by progressive nephron loss involving glomerulosclerosis and tubulointerstitial fibrosis, leading to end stage 
renal disease (ESRD) and need for dialysis. Mortality on dialysis is roughly 30% per year; however, specific 
therapies to prevent, slow down, or reverse fibrosis are severely lacking (3).
Over the course of  ischemic AKI, a variety of  cell types (endothelial cells, neutrophils, T cells, 
macrophages, tubular cells, and pericytes) play important roles in injury and repair (4). However, inju-
ry to the proximal tubule cell (PTC) suffices to induce CKD and fibrosis (5), and injured tubular cells 
drive injury and inflammation by releasing profibrotic factors, in particular TGFβ, and by producing 
inflammatory cytokines, including TNFα (6, 7), identifying PTC as a major player in injury and fibrosis.
Tubular repair mechanisms involve the activation of  EGF receptor (EGFR or HER1). While EGFR 
activation is beneficial in the early phases of  epithelial repair in AKI (day 1–2 after injury), sustained 
activation of  EGFR beyond the initial injury repair phase (days to weeks after injury) has been linked to 
kidney fibrosis in mouse models of  bilateral ischemic AKI and unilateral ureteral obstruction (UUO) (8–
13). Sustained activation of  EGFR and its downstream pathways, in particular mitogen activated protein 
kinase (ERK), increases production of  TGFβ (9, 13). TGFβ stimulates interstitial myofibroblasts (derived 
from stromal cells, most likely vascular pericytes; ref. 14) to proliferate and to secrete collagen and other 
matrix proteins, thus driving interstitial fibrosis and functional disruption of  nephrons.
A disintegrin and metalloprotease 17 (ADAM17, also named TACE) releases the ectodomains of  
Kidney fibrosis following kidney injury is an unresolved health problem and causes significant 
morbidity and mortality worldwide. In a study into its molecular mechanism, we identified 
essential causative features. Acute or chronic kidney injury causes sustained elevation of a 
disintegrin and metalloprotease 17 (ADAM17); of its cleavage-activated proligand substrates, 
in particular of pro-TNFα and the EGFR ligand amphiregulin (pro-AREG); and of the substrates’ 
receptors. As a consequence, EGFR is persistently activated and triggers the synthesis and release 
of proinflammatory and profibrotic factors, resulting in macrophage/neutrophil ingress and 
fibrosis. ADAM17 hypomorphic mice, specific ADAM17 inhibitor–treated WT mice, or mice with 
inducible KO of ADAM17 in proximal tubule (Slc34a1-Cre) were significantly protected against these 
effects. In vitro, in proximal tubule cells, we show that AREG has unique profibrotic actions that 
are potentiated by TNFα-induced AREG cleavage. In vivo, in acute kidney injury (AKI) and chronic 
kidney disease (CKD, fibrosis) patients, soluble AREG is indeed highly upregulated in human urine, 
and both ADAM17 and AREG expression show strong positive correlation with fibrosis markers in 
related kidney biopsies. Our results indicate that targeting of the ADAM17 pathway represents a 
therapeutic target for human kidney fibrosis.
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most EGFR ligands and of  TNFα from their transmembrane proforms to produce active soluble ligands 
(ectodomain shedding) (15). In vivo, in mouse and humans, pro-HER ligands and pro-TNFα represent 
ADAM17’s physiologically dominant substrates (16, 17). Several EGFR ligands, including HB-EGF 
and EGF, have been associated with proliferative and migratory responses of  tubular cells in vitro, and 
HB-EGF, TGFα, and EGF have been shown to hasten tubular recovery and limit injury after AKI in vivo 
(18–20). Interestingly, HB-EGF and TGFα, at the same time, have also been linked to glomerular sclerosis 
and kidney fibrosis (21–23), but it is unknown what causes these different outcomes. The role of  other 
EGFR ligands, including epiregulin (EREG), epigen, amphiregulin (AREG), or betacellulin has not been 
examined in AKI or its transition to kidney fibrosis to date. The other main ADAM17 substrate, pro-TN-
Fα, is an inflammatory cytokine and a major driver of  kidney injury, promoting inflammation, apoptosis, 
and glomerular barrier damage (24). However, the effects of  TNFα inhibition on kidney fibrosis and CKD 
progression are uncertain (25, 26). Thus, it is largely unknown which mechanisms sustain profibrotic acti-
vation of  EGFR in the injured kidney, which specific HER ligands or other HER receptors are involved, 
and what role TNFα contributes. It is further unknown whether ADAM17 pathway upregulation is rele-
vant in human AKI or CKD.
We report here that proximal tubule ADAM17 pathway upregulation and activation causes sustained 
EGFR activation and fibrosis after kidney injury (including ischemia and ureteral obstruction) via several 
cellular mechanisms in vitro and in vivo: ADAM17-induced upregulation of  its own pathway (substrates 
and their receptors), unique profibrotic actions of  its EGFR ligand substrate pro-AREG and EGFR-TNFα 
pathway crosstalk. Using 3 independent approaches/models targeting ADAM17, ADAM17 hypomorphic 
mice, specific ADADM17 inhibitor–treated WT mice, or mice with inducible genetic deletion of  ADAM17 
in the proximal tubule, we show strong protection against ADAM17 pathway upregulation and subse-
quent fibrosis. We further show that, in biopsy and urine samples of  AKI and CKD patients with fibrosis, 
ADAM17 pathway activation also occurs and correlates significantly with markers of  fibrosis, highlighting 
ADAM17 pathway inhibition as a potential therapeutic target in AKI and CKD in humans.
Results
ADAM17ex/ex mice show decreased fibrosis after bilateral ischemia reperfusion injury (IRI). ADAM17ex/ex hypo-
morphic mice with very low ADAM17 expression in all cells (<5% of  WT) have an introduced exon 
between exons 11 and 12 of  the ADAM17 gene (17). This new exon not only carries an in-frame stop 
codon, but is also flanked by splice donor acceptor sites, which slightly deviate from the canonical sequenc-
es. Therefore, the new exon is used in over 95% of  cases and leads to abortion of  translation. Less than 5% 
of  the time, full-length ADAM17 mRNA is produced; this keeps the animals viable. To examine the role 
of  ADAM17 in AKI, we subjected WT and ADAM17ex/ex mice to severe bilateral IRI (clamping of  both 
renal vascular supplies for 30 minutes) and sacrificed them at different time points after injury (day 1–42).
To assess the degree of  initial injury, we compared upregulation of  injury markers, tubular damage, 
and downregulation of  CD31 staining as a marker of  endothelial injury and cell loss in both genotypes. 
Serum creatinine (determined by mass spectometry) and blood urea nitrogen (BUN), 2 markers of  glo-
merular filtration rate, were increased by IRI to similar values (creatinine: 1.02 ± 0.12 vs. 0.96 ± 0.14 mg/
dl; BUN: 95.52 ± 8.35 vs. 87.74 ± 5.82 mg/dl) 24 hours after ischemia (Figure 1, A and B) and were, at 
no time during recovery, significantly different between the 2 groups. This recovery plateaued at about 3× 
baseline creatinine value (0.2 mg/dl) at 21–42 days, indicating significant loss of  kidney function (about 
50%–70% glomerular filtration rate) as well as substantial and equal functional compensation in both geno-
types (Figure 1, A and B). In both genotypes, urinary levels of  kidney injury molecule 1 (KIM1) — a widely 
used kidney injury marker (Figure 1C) — and severe cortical tubular injury at 24 hours after ischemia 
(Figure 1D) were also similar. After 24 hours and up to 42 days after IRI, peritubular CD31-endothelial 
cell staining was decreased compared with sham-operated mice but did not show significant differences 
between ADAM17ex/ex and WT mice at any time tested, suggesting that peritubular capillary vessels 
and endothelial cells were equally preserved (Figure 1E). Collectively, these results indicate that the initial 
severe kidney injury was not significantly different between ADAM17ex/ex and their WT littermates.
Despite a similar degree of  initial injury, other kidney outcomes varied significantly between WT and 
ADAM17ex/ex mice. On day 21 and 42 after injury, kidneys of  ADAM17ex/ex mice showed strongly 
reduced production of  the profibrotic markers α smooth muscle actin (αSMA) and fibronectin, as detected 
by IHC (Figure 1F [day 21] and Supplemental Figure 1 [day 42]; supplemental material available online 
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Figure 1. Global targeting of ADAM17 results in similar initial IRI-induced injury but in reduced IRI-induced fibrosis. ADAM17ex/ex mice and their 
WT littermates were subjected to bilateral ischemia for 30 minutes followed by reperfusion. (A and B) Time-course of changes in serum creatinine 
and BUN (n = 6–15 per time point). (C) Time-course of urinary KIM1 levels over time measured by ELISA (n = 5–10 per time point). (D) Tubular damage 
was scored in kidney cortex at day 1 after ischemia (n = 6–7). (E) Time course of cortical CD31+ area quantified after immunostaining (n = 4). (F) The 
induction of fibronectin and αSMA in kidney cortex was examined by immunostaining 21 days after injury (top: representative images; bottom: 
quantification, n = 6; scale bar: 50 μm). (G) Fibronectin protein expression at day 21 after injury was examined by Western blot (left: sample blots; 
right: quantification; GAPDH was used as loading control; n = 5). (H and I) Masson’s trichrome staining at day 21 after injury in kidney cortex (H: rep-
resentative images; I: quantification; n = 6; scale bar: 100 μm). (J) Total interstitial area (n = 6) and (K) dilated tubules were quantified at day 21 after 
injury (n = 6). (L) Soluble TNFα was measured by ELISA in control (WT/WT), hypomorphic (ex/ex), and WT mice injected with recombinant ADAM17 
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with this article; doi:10.1172/jci.insight.87023DS1) and Western blot (Figure 1G). Consistent with this, 
ADAM17ex/ex mice showed reduced interstitial collagen deposition in the kidney cortex (Figure 1, H 
and I, Masson’s stain), reduced overall expansion of  interstitial area (Figure 1J), and a reduced number of  
dilated tubules (Figure 1K) — all characteristics of  persistent tubulo-interstitial injury and disruption of  
structural nephron integrity. Thus, ADAM17 is involved in the development of  delayed fibrosis after AKI 
injury, and the ADAM17 low state is protective.
ADAM17 prodomain inhibitor blocks ADAM17 substrate cleavage in vivo and confers protection against IRI-in-
duced fibrosis. To ensure that the above described effects in ADAM17ex/ex mice depended on reduced 
ADAM17 catalytic activity, we treated WT mice with recombinant ADAM17 prodomain. The prodomain 
of  ADAM17 blocks its catalytic site and is usually cleaved during trafficking of  the molecule to the cell 
surface by a furin-type protease. It, however, can stay associated with the molecule on the cell surface until 
it is removed by a second cleavage event within the prodomain sequence carried out by an unknown prote-
ase (27). The prodomain used in our experiments has a mutated internal furin cleavage site and cannot be 
actively removed from the protease (28). When injected into tail vein or i.p., the prodomain inhibitor can 
be readily detected at high levels in various organs, including the kidney (data not shown). Compared with 
vehicle controls, daily i.p. prodomain injections resulted in reduced amounts of  soluble TNFα ectodomain 
in kidney lysates (Figure 1L) and in reduced levels of  αSMA and fibronectin protein 5 days after ischemia 
(Figure 1M). These results confirmed that ADAM17 activity is required for its profibrotic function, but it 
remains unresolved as to which cells ADAM17 activity is most important in.
Proximal tubule-specific ADAM17 KO confers protection against fibrosis after IRI. Although EGFR deletion in 
most tubular cells (using a γ-glutamyltransferase 1-Cre [γGT-Cre] to confer relative specificity to the proxi-
mal tubule) confers protection against fibrosis in several kidney injury models (9, 22), the source of  EGFR 
ligands and the specific tubular cell compartment of  EGFR action remain unknown. Since the proximal 
tubule generates important kidney injury signals (6, 7) and ADAM17 is a ubiquitiously expressed protease, 
we first dissected its role in PTC.
We generated ADAM17 PTC-KO mice by crossing ADAM17fl/fl mice with mice expressing Cre recom-
binase under control of  the tamoxifen-inducible Slc34a1 promoter, a transport protein expressed only in the 
proximal S1/S2 segments of  the PTC (29). We compared SLC34a1GCE/+ ADAM17fl/fl (ADAM17 PTC-KO) 
with SLC34a1GCE/+ ADAM17WT/WT mice; Cre was present in both experimental groups, and all mice were 
injected with tamoxifen. In WT kidneys, ADAM17 was broadly expressed in proximal (PTC brush-border 
marker Lotus tetragonolobus lectin–positive [LTL-positive]; thick arrows) and distal tubule (LTL-negative; 
thin arrows) segments, as well as glomeruli and interstitial cells (Figure 2A; left panel). After tamoxifen 
injection into ADAM17 PTC-KO mice, ADAM17 was specifically deleted only in LTL-positive proximal 
tubule cells (thick arrows) but not in distal tubular segments (thin arrows) (Figure 2A, right panel). We 
then subjected ADAM17 PTC-KO mice and their WT littermates to bilateral IRI. Since the S3 segment 
is the most vulnerable PTC segment to ischemic injury, we ensured that our severe bilateral IRI protocol 
resulted in damage to all proximal tubule segments (S1-3) throughout the cortex, identical to our approach 
in ADAM17ex/ex mice.
Bilateral renal IRI caused similar injury and recovery as measured by injury markers BUN, NGAL, 
and KIM1 in both genotypes over time (Figure 2, B–D). However, as in our experiments with ADAM17 
hypomorphic mice, functional recovery was only partial, and propensity to develop fibrosis differed sub-
stantially. Three weeks after ischemia, ADAM17 PTC-KO — as compared with WT littermates — showed 
significantly reduced fibronectin and αSMA protein production (Figure 2E; immunofluorescence [IF]), 
reduced fibronectin protein expression (Figure 2F, Western blot), reduced interstitial collagen production 
(Figure 2, G and H, Masson’s stain), less total interstitial area (Figure 2I), and reduced tubular dilation (Fig-
ure 2J). Thus, inducible specific ADAM17 KO in the very proximal segments of  the proximal tubule can 
phenocopy, in terms of  fibrosis, hypomorphic mice with very low ADAM17 in all cells, defining ADAM17 
and its substrates localized in PTC as central players in IRI-induced kidney injury and fibrosis.
prodomain (WT/WT+A17pro) 2 days after injury (n = 4). (M) The induction of fibronectin and αSMA was examined in kidney cortex by immunostaining 
in vehicle or ADAM17 prodomain inhibitor–injected WT mice 5 days after injury (left: representative images, right: quantification; n = 4; scale bar: 50 
μm). *P < 0.05; **P < 0.01; ***P < 0.001 as determined by an unpaired 2-tailed Student’s t test. Diamond symbol denotes position of kidney capsule. 
ADAM17, a disintegrin and metalloprotease 17; BUN, blood urea nitrogen; IRI, ischemia reperfusion injury; KIM1, kidney injury molecule 1; MT, Mas-
son’s trichrome; αSMA, alpha smooth muscle actin; TNFα, tumor necrosis factor alpha; WB, Western blot.
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Figure 2. Proximal tubular-specific ADAM17 KO confers protection against fibrosis after IRI. Control (SLC34a1GCE/+ ADAM17WT/WT, Cre WT/WT) and 
ADAM17 PTC-KO (SLC34a1GCE/+ ADAM17fl/fl, Cre fl/fl) mice were subjected to bilateral ischemia for 29 minutes followed by reperfusion. (A) KO specificity was 
examined in healthy kidneys (left: control, right: PTC-KO mouse) by immunostaining of ADAM17 (red color) together with LTL staining (green color) as a 
proximal tubular marker (thick arrows, LTL-positive tubules; thin arrows, LTL-negative tubules; scale bar: 50 μm). (B–D) Time-course of BUN, urinary NGAL, 
and urinary KIM1 (n = 6–15). (E) The induction of fibronectin and αSMA was examined in kidney cortex by immunostaining at day 21 (left: representative 
images, right: quantification, n = 10; scale bar: 50 μm). (F) Fibronectin protein expression at day 21 after injury was examined by Western blot (top: sample 
blots; bottom: quantification; GAPDH was used as loading control; n = 4). (G and H) Masson’s trichrome staining in kidney cortex at day 21 after injury (G: 
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ADAM17ex/ex and PTC-KO mice are protected against fibrosis caused by ureteral obstruction. To test whether 
protection against fibrosis extended to other injuries beyond ischemia, we used a different model of  kidney 
fibrosis, UUO. ADAM17ex/ex mice and WT littermates were subjected to UUO and examined after 7 and 
14 days. Similar to IRI, ADAM17ex/ex mice injured with UUO showed reduced αSMA and fibronectin 
at the mRNA (Figure 3A) and protein levels (Figure 3B, IF, and Figure 3C, Western blot) and signifi-
cantly reduced interstitial fibrosis as compared with WT mice (Figure 3D; Masson’s stain). Very similar 
results were obtained in ADAM17 PTC-KO mice subjected to UUO (Figure 3, E–H), suggesting that the 
ADAM17 pathway in PTC represents a central signaling hub relevant to kidney fibrosis that responds to 
various tubular injuries.
Genetic deletion of  ADAM17 in kidney stroma (stroma-KO) using FoxD1-Cre (Supplemental Figure 
2A; KO specificity verified by immunostaining; ref. 14) conferred no substantial protective effect against 
fibrosis induced by UUO (Supplemental Figure 2B), suggesting that myofibroblasts are not a major source 
of  ADAM17-cleaved signals that promote fibrosis in this injury model.
Injury-induced ADAM17 pathway upregulation causes sustained EGFR activation in WT mice, while this effect 
of  injury is impaired in ADAM17ex/ex mice. In order to identify which ADAM17 substrates and which of  
their receptors carry out the observed ADAM17 profibrotic function, we examined its pathway induction 
in vivo. In WT mice, kidney injury (IRI or UUO) caused upregulation of  the entire ADAM17 pathway, 
including ADAM17, its EGF ligand, and TNFα substrates, as well as their receptors.
In WT mice, ADAM17 whole kidney mRNA expression was strongly increased 2 days after injury 
(more than 5-fold compared with sham-operated mice), remained elevated for at least 21 days, and returned 
close to baseline by 42 days (Figure 4A). However, in ADAM17ex/ex mice, no ADAM17 mRNA increase 
was detectable for at least 5 days after ischemia. Only by 21 days, we detected a moderate increase (about 
2.7-fold over sham), but ADAM17 mRNA returned to almost baseline at 42 days (Figure 4A). Similarly, 
after UUO, ADAM17 mRNA levels were elevated at day 7 in WT mice and remained low in ADAM17ex/
ex mice (Supplemental Figure 3A). Consistent with the detected mRNA levels, ADAM17 protein was 
strongly increased by ischemia in WT mice (Figure 4B) and remained elevated for at least 21 days (data 
not shown), whereas it was hardly detectable in ADAM17ex/ex mice (Figure 4B) except for a moderate 
elevation at late time points at 21 days after injury (data not shown). ADAM17 upregulation at late time 
points occurs due to the fact that, in hypomorphic mice, a full-length ADAM17 protein is still produced less 
than 5% of  the time and indicates that mechanisms of  ADAM17 upregulation after injury are principally 
intact in ADAM17ex/ex mice.
The mRNAs of  ADAM17 substrate pro-EGFR ligands (HB-EGF, AREG, EREG, TGFα) and pro-TN-
Fα, as well as their corresponding receptors EGFR and TNFR1/2, were significantly increased by injury in 
WT mice, but this effect was blunted in ex/ex mice. In WT mice, AREG was substantially more upregulated 
on day 1–21 than any other EGFR ligand in both mouse models tested (Figure 4C [IRI] and Supplemental 
Figure 3B [UUO]) while mRNA expression of  the EGFR ligand and ADAM10 substrate EGF remained at 
very low levels after injury (Figure 4C [IRI] and Supplemental Figure 3B [UUO]). In contrast, ADAM17ex/
ex mice showed only very mild to moderate increases of  EGFR ligand mRNA expression on day 1 after 
injury; the expression returned to almost basal levels by day 2 and remained low for at least 5 days after inju-
ry (Figure 4D [IRI] and Supplemental Figure 3B [UUO, day 7]). On the receptor level, EGFR was strongly 
upregulated in injured WT mice over at least 5 days, but not in ex/ex mice, which only showed a moderate 
increase by day 21 (Figure 4E [IRI] and Supplemental Figure 3A [UUO, day 7]). TNFα and its receptors fol-
lowed a similar pattern. TNFα and TNFR1/2 in WT mice were strongly increased by injury on day 1–2 and 
remained high for at least 5 days; TNFα and TNFR1/2 expression in ex/ex mice was moderately elevated 
similar to WT mice on day 1, returned to baseline levels by day 2, and only showed a moderate late second 
peak of  expression increase by day 5 (Figure 4, F–H [IRI], and Supplemental Figure 3A [UUO]).
As a result of  these differences in transcriptional and translational factor upregulation (mRNA and 
protein level), ADAM17ex/ex mice as compared with WT mice also showed strong differences in post-
representative images; H: quantification; n = 6; scale bar: 100 μm). (I) Total interstitial area (n = 6) and (J) dilated tubules (n = 6) were quantified in kidney 
cortex at day 21 after injury. *P < 0.05; **P < 0.01; ***P < 0.001 as determined by an unpaired 2-tailed Student’s t test. Diamond symbol denotes position 
of kidney capsule. ADAM17, a disintegrin and metalloprotease 17; BUN, blood urea nitrogen; IRI, ischemia reperfusion injury; KIM1, kidney injury molecule 1; 
LTL, Lotus Tetragonolobus lectin; MT, Masson’s trichrome; NGAL, neutrophil gelatinase–associated lipocalin; PTC-KO, proximal tubule cell KO; αSMA, alpha 
smooth muscle actin; WB, Western blot.
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Figure 3. ADAM17ex/ex and ADAM17 PTC-KO mice are protected from UUO-induced fibrosis. Mice were subjected to UUO, and their kidneys were 
examined 7 or 14 days after ureteral ligation, as noted. (A) qPCR analysis of fibronectin or αSMA mRNA expression levels in whole kidneys of ex/ex 
or WT/WT mice at day 7, expressed as fold over respective sham-injured mice (n = 6). (B) The induction of fibronectin and αSMA in the injured kidney 
cortex of UUO-subjected WT/WT or ex/ex mice was examined by immunostaining (left: representative images; right: quantification; n = 6; scale bar: 
50 μm). (C) Fibronectin protein expression at day 7 after ligation was examined by Western blot (top: sample blots; bottom: quantification; GAPDH 
was used as loading control; n = 3). (D) Masson’s trichrome staining in kidney cortex at day 7 or day 14 after ligation (left: representative images day 
14; right: quantification; n = 5–6; scale bar: 100 μm). (E) qPCR analysis of fibronectin or αSMA mRNA expression levels in whole kidneys of UUO-sub-
jected control (Cre WT/WT) or ADAM17 PTC-KO (Cre fl/fl) at day 7, expressed as fold over respective sham-injured mice (n = 3). (F) The induction of 
fibronectin and αSMA in the injured kidney cortex of UUO-subjected control (Cre WT/WT) or ADAM17 PTC-KO (Cre fl/fl) mice was examined at day 
7 by immunostaining (left: representative images, right: quantification; n = 5; scale bar: 50 μm). (G) Fibronectin protein expression at day 7 after 
ligation was examined by Western blot (top: sample blots; bottom: quantification; GAPDH was used as loading control; n = 3). (H) Masson’s trichrome 
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R E S E A R C H  A R T I C L E
translational modification of  ADAM17 substrates, with much reduced TNFα and EGFR ligand cleavage in 
vivo after injury (Figure 4I; ADAM10 substrate cMet is shown as a control) and strongly reduced or absent 
phosphorylation of  EGFR on days 1–5 after injury, examined by Western blot and immunostaining (Fig-
ures 4, J and K [IRI], and Supplemental Figure 3C [UUO]). Further, using the ADAM17 PTC-KO mouse 
model, we also saw very similar upregulation of  the ADAM17 pathway in WT littermates subjected to 
both IRI or UUO, with AREG being the most upregulated EGFR ligand (~100-fold higher than any other 
EGFR ligand; data not shown).
In conclusion, the absence of  injury-induced ADAM17 upregulation and lack of  its cleavage activity 
appears to reduce upregulation of  its downstream signaling pathways, suggesting the existence of  posi-
tive-feedback loops. We hypothesized based on our observations in vivo that ADAM17 and its substrates 
produce ligands that, in turn, enhance their own transcriptional upregulation or activity and involve, in 
particular, the action of  AREG (EGFR ligand) as well as the TNFα pathway, leading to sustained profi-
brotic EGFR activation.
AREG more than any other EGFR ligand causes ADAM17 pathway upregulation and expression of  profibrotic 
and proinflammatory mediators in vitro in mouse and human PTC; crosstalk with the TNFα pathway strongly poten-
tiates this effect. For the in vitro analysis of  ADAM17 dependent pathways, we used mouse primary tubular 
cells isolated from WT and ADAM17ex/ex mice, as well as a human PTC line (HPTC). AREG, in com-
parison to any other EGFR ligand, and also TNFα, potentiated the expression of  their own pathway com-
ponents (the effect of  all ADAM17 EGF ligand substrates tested is shown in Supplemental Figure 4). Thus, 
AREG induced the expression of  AREG itself, ADAM17, TGFα, and HB-EGF, while TNFα induced 
the expression of  TNFα itself  and TNFR2 (Figure 5A). More importantly, however, we found significant 
crosstalk between both pathways, likely potentiating their individual injurious actions in vitro and in vivo.
Exposure of  HPTC to TNFα resulted in significant upregulation of  mRNA expression of  EREG, as 
well as of  AREG (Figure 5A). Conversely, AREG potently induced the expression of  TNFR2 (Figure 5A). 
These results confirm the hypothesis that ADAM17-cleaved ligands, in particular AREG and TNFα, drive 
positive-feedback loops that enhance expression and activation of  their own individual pathways; however, 
both ADAM17-dependent pathways also crosstalk and synergize in their actions. This synergistic action 
can, for example, be observed on the level of  the production of  profibrotic and proinflammatory cyto-
kines. When compared with any other EGFR ligand (added in isomolecular amounts), AREG stimulated 
significantly more mRNA production of  TGFβ, a potent profibrotic cytokine, as well as of  monocyte che-
moattractant protein 1 (MCP1), of  macrophage inflammatory protein 1 alpha (MIP1A), and of  regulated 
on activation normal t cells expressed and secreted (RANTES) — cytokines involved in monocyte/mac-
rophage recruitment after kidney injury (Figure 5B and Supplemental Figure 4). TNFα, as expected, also 
strongly induced the same proinflammatory molecules; however, when used in combination with AREG, 
its effects were significantly potentiated (Figure 5B). Interestingly, TNFα stimulation caused AREG cleav-
age in HPTC (Figure 5C), suggesting an important upstream crosstalk mechanism that would potentiate 
and sustain EGFR activation and its profibrotic action. These results strongly suggest that the profibrotic 
function of  ADAM17 is due to the concerted injurious actions of  its EGFR ligand substrates, in particular 
AREG, and of  TNFα.
AREG causes sustained EGFR activation in proximal tubule cells in a cleavage-dependent manner. Whether 
different ligands have differential effects on activation of  EGFR and its downstream pathways, and which 
are the implicated mechanisms, is not well understood. We exposed HPTC to isomolecular amounts of  
AREG and HB-EGF, the ligands with the strongest and the weakest effect on EGFR pathway induction in 
HPTC (Supplemental Figure 4), and examined their effects on EGFR activation, as well as the activation 
of  EGFR downstream targets. HB-EGF induced fast, strong, short-lasting phosphorylation of  EGFR at 
Y1068 starting at 5 minutes and returning to baseline levels by 4 hours (Figure 5, D and G). In contrast, 
AREG resulted in a biphasic phosphorylation pattern of  EGFR and its downstream effectors ERK1/2, 
with mild-to-moderate early phosphorylation and a second peak of  long-lasting phosphorylation starting at 
about 8 hours and lasting at least 24 hours (Figure 5, E and G). To test whether the second peak of  EGFR 
staining in kidney cortex at day 7 after ligation in control (Cre WT/WT) or ADAM17 PTC-KO (Cre fl/fl) mice (left: representative images; right: quanti-
fication; n = 6; scale bar: 100 μm). *P < 0.05; **P < 0.01; ***P < 0.001 as determined by an unpaired 2-tailed Student’s t test. ADAM17; a disintegrin 
and metalloprotease 17; FN1, fibronectin; MT, Masson’s trichrome; PTC-KO, proximal tubule cell KO; αSMA, alpha smooth muscle actin; UUO, unilat-
eral ureteral obstruction; WB, Western blot.
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Figure 4. IRI-induced ADAM17 pathway components are reduced in ADAM17ex/ex mice. The expression levels of ADAM17 and its pathway components 
were examined at different time points after ischemic injury in whole kidneys. (A) qPCR analysis of ADAM17 mRNA expression levels in ex/ex or WT/WT 
mice, expressed as fold over respective sham-injured mice (n = 3–5). (B) Western blot analysis of ADAM17 protein levels in ex/ex or WT/WT mice subjected 
to sham or IRI (day 5 after ischemia) (left: sample blots; right: quantification; GAPDH was used as loading control; n = 5). (C–H) qPCR analysis of EGFR 
ligands, EGFR, TNFα, and TNFR1/2 mRNA expression levels in ex/ex or WT/WT mice, expressed as fold over respective sham-injured mice (time points as 
indicated; n = 3–6). (I) Soluble ectodomains of the ADAM17 substrates TNFα, TGFα, and AREG were measured in whole kidney lysates of WT/WT or ex/ex 
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phosphorylation requires the cleavage of  EGFR ligands, we exposed HPTC to AREG in the presence of  
the metalloprotease inhibitor BB94. We found that, although the initial EGFR phosphorylation peak is not 
affected (as expected), the second peak is abolished (Figure 5, F and G). These results suggest that AREG 
sustains EGFR activation in PTC in vitro (and likely in vivo) via a positive feedback loop that includes 
upregulation of  the expression (Figure 5A) and subsequent cleavage (Figure 5, C, F, and G) of  EGFR 
ligands (as measured by EGFR phosphorylation), including prominently AREG itself.
Injury-induced cytokine expression, as well as kidney ingress of  neutrophils and macrophages, is reduced in vivo in 
ADAM17ex/ex and ADAM17 PTC-KO mice. Given these observed effects of  soluble ADAM17 substrates on 
the production of  profibrotic and proinflammatory cytokines in PTC in vitro, we also examined the induc-
tion of  these cytokines after injury in vivo. ADAM17ex/ex mice showed reduced levels of  both TGFβ and 
MCP1 expression at 1–5 days after ischemia compared with WT littermates (Figure 6, A and B). Reduced 
production of  TGFβ correlated with reduced levels of  αSMA and fibrosis in all our injury models (Figures 
1–3) and with the reduced induction of  the myofibroblast marker PDGFRβ (Figure 6C). Reduced levels 
of  proinflammatory cytokines were associated with significantly reduced accumulation of  immune cells in 
the kidney. As compared with WT mice, macrophage ingress into the kidney — quantified by F4/80 stain-
ing — was diminished in ADAM17ex/ex mice at 3, 5, or 21 days after ischemia, as well as at 7 days after 
UUO (Figure 6D). Neutrophil infiltration at days 1 and 5 after ischemia was also reduced in ADAM17ex/
ex mice (Figure 6E). In ADAM17 PTC-KO mice, as compared with their WT littermates, we only saw a 
nonsignificant trend of  reduction of  macrophage ingress in IRI experiments at the time points measured, 
but we detected a significant reduction at day 7 in the UUO experiments (Figure 6F). In terms of  neutrophil 
ingress, we detected a significant reduction at day 1 after IRI when neutrophil levels were high in WT mice, 
while no differences between WT mice and ADAM17 PTC-KO mice were detectable at day 5, when both 
genotypes showed very low levels of  neutrophils (Figure 6G).
In conclusion, injury-induced proximal tubule ADAM17 substrate cleavage in vivo — presumably pre-
dominantly involving AREG and TNFα as shown in our in vivo and in vitro experiments — leads to the 
release of  proinflammatory cytokines, resulting in recruitment of  neutrophils and macrophages and the 
production of  the profibrotic cytokine TGFβ, which together drive fibrosis.
ADAM17, AREG, and TNFR1 expression and EGFR phosphorylation are increased in human AKI and 
CKD. To examine whether ADAM17-dependent pathways, as suggested by our mouse studies, are also 
induced in human kidney disease, we examined the expression levels of  ADAM17 and AREG and the 
activation of  EGFR in human kidney biopsies (Brigham and Women’s Hospital kidney biobank). We 
tested 3 different diagnosis — 4 patients each — and show representative images in Figure 7: hyper-
oxaluria (HOX; intraluminal tubular obstruction of  urine flow as it occurs in crystal-forming oxaluria 
patients represents a more proximal but pathogenetically similar mechanism to UUO in mice), glomer-
ulonephritis (GN), and diabetic nephropathy (DN). Most samples showed evidence of  tubulo-inter-
stitial fibrosis as determined by a pathologist (based on Masson’s trichrome stain) and also by immu-
nostaining for the fibrotic marker αSMA as compared with control samples (Figure 7A, first column). 
Similar to mice, we found that tubular and interstitial ADAM17 expression, tested by immunostaining, 
was strongly increased in most human kidney tissue samples (Figure 7A, second column). Concurrent-
ly, we found increased expression of  AREG (Figure 7A, third column), as well as increased activation 
of  EGFR, as measured by a phosphospecific EGFR antibody (Figure 7A, fourth column). Interestingly, 
the amount of  the profibrotic marker αSMA expressed in tissue samples across all patients and condi-
tions was positively and strongly correlated with ADAM17 or AREG expression (Figure 7, B and C), 
suggesting a strong link between ADAM17 expression level and fibrosis in human kidney disease.
In addition, we examined the levels of  ADAM17-cleaved substrates in urine sample of  AKI and 
CKD patients (Figure 8; see also patient characteristics in Supplemental Table 1). Interestingly, soluble 
AREG and TNFR1 were very significantly and strongly upregulated in the urine samples of  patients 
mice at day 2 after ischemia by ELISA (ADAM10 substrate cMET is used as control; n = 4). (J) Time-course of EGFR phosphorylation (Y1068) as measured 
by Western blot in whole kidney lysates of WT/WT or ex/ex mice (n = 5). (K) Representative images of EGFR phosphorylation (Y1173) examined in kidney 
cortex by immunostaining in WT/WT or ex/ex mice at day 2 after injury (left: representative images; right: quantification; n = 3; scale bar: 50 μm). *P < 
0.05; **P < 0.01; ***P < 0.001 as determined by an unpaired 2-tailed Student’s t test. ADAM17; a disintegrin and metalloprotease 17; EGFR, epidermal 
growth factor receptor; IRI, ischemia reperfusion injury; NS, nonspecific band; TNFα, tumor necrosis factor α; TNFR, tumor necrosis factor receptor; AREG, 
amphiregulin; ADAM10, a disintegrin and metalloprotease 10; cMet, met proto-oncogene; WB, Western blot.
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with severe AKI and tubular necrosis (Figure 8, A and B), a condition prone to the development of  
fibrosis, in mice (as shown in our experiments) and in humans (4, 30, 31). AREG and TNFR1 were also 
moderately upregulated in the urine of  patients with fibrotic CKD (many of  them diabetics) (Figure 8, A 
and B). AREG, in fact, was the only EGFR ligand tested that was significantly upregulated under both 
of  these conditions. HB-EGF was modestly but significantly upregulated in the AKI group (Figure 8C), 
and TGFα was upregulated in none of  the conditions as compared with control (Figure 8D). We failed 
to detect the presence of  soluble TNFα in human urine samples, but the presence of  soluble TNFR1 sug-
gests activity of  ADAM17 and the TNFα pathway in human AKI and CKD, since — besides TNFα — its 
receptors TNFR1 and TNFR2 are also ADAM17 substrates (32, 33). In accordance with our results in 
mice, these findings thus suggest a possible involvement of  ADAM17 and activation of  its main physio-
logical downstream pathways, EGFR (likely via AREG) and TNFα/TNFR, in AKI and chronic fibrotic 
kidney disease in humans. A summary of  our results is provided in a schematic in Figure 9.
Discussion
Our results demonstrate the protective effect of  inhibition of  ADAM17-mediated release of  EGFR ligands 
and TNFα against kidney fibrosis that develops after different kidney injuries (AKI, UUO), suggesting a 
central role of  ADAM17 in fibrotic kidney diseases. Using an inducible ADAM17 KO specific to only the 
first 2 segments of  the proximal tubule (Slc34a1-Cre), we identified the proximal tubule as the source of  
EGF ligands that drives tubular EGFR activation in fibrosis. Our results corroborate other reports that 
show that sustained tubular EGFR activation after AKI or UUO drives kidney fibrosis in WT mice, while 
mice with low EGFR activity (wa2 mice), EGFR inhibition, or EGFR deletion in tubular cells (γGT-Cre) 
were protected (9, 11, 13).
Some studies reported that AKI-induced fibrosis is mediated by ligand-independent activation of  
EGFR by SRC kinase at Y845 and might involve production of  ROS (9, 34). Our results, however, sug-
Figure 5. Amphiregulin (AREG) and TNFα 
crosstalk causes sustained EGFR activation 
and strongly enhanced cytokine production 
in human proximal tubular cells. (A and B) 
qPCR analysis of ADAM17 pathway compo-
nents (A) and proinflammatory/profibrotic 
cytokines (B) in human proximal tubular cells 
treated with AREG, TNFα, or both (AREG+T-
NFα) for 24 hours (n = 4). (C) Time course 
of TNFα-induced AREG cleavage producing 
soluble AREG (sAREG) measured by ELISA 
in HPTC culture medium (n = 3). (D–F) Time 
course of HB-EGF–induced (D) or AREG-in-
duced (E and F) Y1068-EGFR and ERK1/2 
phosphorylation (analyzed by Western blot) 
in the absence (D and E) or presence (F) of 
the metalloprotease inhibitor BB94. Tubulin 
is used as loading control for quantification 
(G; n = 3). *P < 0.05; **P < 0.01 as determined 
by an unpaired 2-tailed Student’s t test. 
ADAM17, a disintegrin and metalloprotease 
17; AREG, amphiregulin; BB94, batimastat; 
EGF, epidermal growth factor; EGFR, epider-
mal growth factor receptor; EREG, epiregulin; 
ERK, extracellular regulated mitogen activat-
ed protein kinase; HB-EGF, heparin binding 
epidermal growth factor-like growth factor; 
HPTC, human proximal tubule cells; MCP1, 
monocyte chemoattractant protein 1; MIP1A, 
macrophage inflammatory protein 1 alpha; 
MIP1B, macrophage inflammatory protein 
1 beta; RANTES, regulated on activation 
normal T cell expressed and secreted; TNFα, 
tumor necrosis factor alpha; TNFR, tumor 
necrosis factor receptor.
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gest that it is the release of  EGF ligand ADAM17 substrates that causes EGFR activation. We have only 
observed low EGFR Y845 phosphorylation in our studies at all time points examined (data not shown). 
Complicating the interpretation of  this issue is the fact that SRC can be activated by EGFR itself, making 
it difficult to examine whether the action of  SRC is upstream or downstream of  EGFR activation. Of  
note, some studies have implicated ROS (35) and also SRC in the activation of  ADAM17 (36). Taking all 
evidence into account, it is thus possible that Y845 phosphorylation by SRC represents an additional mod-
ulatory pathway to sustain ligand-dependent EGFR activation after injury.
Since all major cell types in the injured kidney can produce or respond to elevated amounts of  EGFR 
ligands or TNFα (6, 37), analysis of  their cause and effect in kidney injury and fibrosis has been complicat-
ed. Our ADAM17 PTC-KO clearly shows that the PTC is responsible for sending an injurious profibrot-
ic signal (chronic EGFR ligand and TNFα release; proinflammatory cytokine and TGFβ production) to 
tubular cells, stromal cells, neutrophils/macrophages, and possibly endothelial cells. ADAM17 stromal cell 
KO (FoxD1-Cre) was not protective against fibrosis (at least in UUO), suggesting that ADAM17 substrate 
release from fibroblasts does not play a dominant profibrotic role. Thus, stromal cells and (myo)fibroblasts 
derived from them act as downstream effectors of  ADAM17-induced profibrotic signals emanating from 
injured PTC. Our data does not exclude possible profibrotic ADAM17 functions in other kidney cells, but 
the significant reduction in fibrosis afforded by proximal tubule deletion highlights this segment of  the 
nephron as the most important.
Our results strongly implicate interplay of  both physiological ADAM17 downstream pathways — the 
EGFR pathway, with strong evidence for a role of  AREG, and the TNFα pathway — in establishing sus-
tained tubular EGFR activation and fibrosis. AREG was by far the most upregulated EGFR ligand in all 
our kidney injury models and also in human kidney disease samples. AREG has also been found upregu-
lated in mouse lung and liver injury models and in patients with idiopathic pulmonary fibrosis or chronic 
liver injury with fibrosis (38–40). Compared with any other EGFR ligand tested or with TNFα, AREG was 
uniquely able to upregulate itself  (Figure 5 and Supplemental Figure 4) and all ADAM17 pathway compo-
nents, thereby strengthening its own signal; it also caused the most sustained EGFR activation and TGFβ 
Figure 6. Injury-induced cytokine expres-
sion and kidney ingress of macrophages 
and neutrophils is reduced in vivo in 
ADAM17ex/ex and ADAM17 PTC-KO mice. 
(A–C) The mRNA expression of TGFβ, 
MCP1, and PDGFRβ was examined by qPCR 
in whole kidney lysates of WT/WT or ex/
ex mice at different time points after 
ischemia (n = 4). (D–G) Macrophage and 
neutrophil infiltration in the kidney of 
ADAM17ex/ex mice (D and E; n = 5–6) or 
PTC-KO (Cre fl/fl) mice (F and G; n = 4–5) 
and their WT/WT littermates was exam-
ined by immunostaining at different time 
points after ischemia or 7 days after UUO 
(n = 5). *P < 0.05; **P < 0.01;***P < 0.001 
as determined by an unpaired 2-tailed 
Student’s t test. ADAM17, a disintegrin and 
metalloprotease 17; IRI, ischemia reperfu-
sion injury; MCP1, monocyte chemoattrac-
tant protein 1; PDGFRβ, platelet derived 
growth factor receptor beta; PTC-KO, 
proximal tubule cell KO; UUO, unilateral 
ureteral obstruction.
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and inflammatory cytokine production 
in proximal tubule cells. Upregulation of  
the AREG promoter by AREG itself  (in a 
positive-feedback loop) or by other mem-
bers of  the EGF family has been reported 
(41–43). The addition of  TNFα strong-
ly enhanced AREG’s ability to induce 
TGFβ and inflammatory cytokines in our 
in vitro experiments in PTC, suggesting 
strong synergy of  both ADAM17 path-
ways. The nature of  the molecular mecha-
nisms of  TNFα-AREG crosstalk will need 
to be studied in detail but could involve 
TNFα induction of  AREG cleavage itself  
(Figure 5C), as was also reported (e.g., in 
hepatocytes; ref. 44) or the cross-activa-
tion of  similar downstream pathways. Of  
note, at the receptor level soluble AREG acts as a low-affinity EGFR ligand (45), which — in contrast to 
the higher-affinity ligands EGF or HB-EGF — does not lead to significant downregulation of  the receptor 
from the cell surface (46–48). This additional feature might distinguish profibrotic from prorepair EGFR 
ligands and enhance sustained EGFR activation, as shown in our experiments with AREG in PTC.
TNFα cleavage in the kidney in vivo was significantly reduced in ADAM17ex/ex mice and correlated 
with a strong reduction in kidney proinflammatory markers and kidney ingress of  macrophages and neu-
trophils after injury. In ADAM17 PTC-KO mice, we also detected significant reductions in macrophage 
and neutrophil ingress into the kidney after injury. Macrophage ingress showed only a nonsignificant trend 
toward reduction as compared with WT littermates after IRI, but it was significantly reduced after UUO 
(Figure 6F). Neutrophils were significantly reduced after IRI (Figure 6G). It is possible that the observed 
differences in macrophage ingress after IRI between ADAM17ex/ex and ADAM17 PTC-KO mice depend 
in part on differences in mouse background and timing of  examination. However, together with the in vitro 
results obtained in PTC, our overall results in vivo suggest that the proximal tubule represents a significant 
source of  ADAM17-dependent inflammatory signals, such as TNFα and MCP1, that attract macrophages 
and neutrophils into the kidney. Decreased macrophage ingress likely contributes to decreased TNFα 
expression/cleavage in ADAM17 hypomorphic or ADAM17 PTC-KO mice, since macrophages express 
Figure 7. Induction of ADAM17 and AREG pro-
tein expression and EGFR phosphorylation 
in human kidney disease. (A) The presence 
of the fibrotic marker αSMA and of ADAM17, 
AREG, and phospho-EGFR were examined in 
human kidney biopsies by immunostaining. 
Representative images of hyperoxaluria (HOX; 
intrarenal tubular obstruction by crystals not 
shown in image), glomerulonephritis (GN), and 
diabetic nephropathy (DN) cases are shown (4 
controls, 4 HOX, 4 GN, and 4 diabetic patients 
were examined; representative images are 
shown) (thick arrows: positive staining in 
proximal tubular-like structures; thin arrows: 
positive staining in distal tubular-like struc-
tures; scale bar: 50 μm). (B and C) Correlation 
of ADAM17 (B) or AREG (C) protein expression 
levels with αSMA levels across all patients 
studied (n = 9–12). The Pearson correlation 
coefficient (R) and P value are provided in each 
graph. ADAM17; a disintegrin and metallo-
protease 17; AREG, amphiregulin; EGFR, epi-
dermal growth factor receptor; αSMA, alpha 
smooth muscle actin.
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ADAM17 and represent a major source of  TNFα. 
Depletion of  macrophages before ischemia/reperfusion 
indeed diminishes kidney injury; however, the role of  
macrophages in AKI is complex, as they can not only 
play injurious roles, but are also ultimately needed for 
kidney repair (49).
Further supporting TNFα’s involvement in the 
inflammatory component of  AKI, TNFR1 (TNFα 
receptor) KO mice or rats treated with etanercept (TNFα 
neutralizing antibody) show less tubular injury, inflam-
mation, and neutrophil ingress after ischemic AKI (50, 
51). Also, in biopsies of  various human fibrotic kidney 
diseases, ADAM17 expression levels positively correlate 
with the presence of  macrophages (52). Interestingly, 
TNFR1/2 are also ADAM17 substrates (32, 33), and 
soluble TNFR1/2 in serum of  patients is associated 
with the progression of  diabetic kidney disease, which is 
well-known to be associated with progressive tubulo-in-
terstitial fibrosis (53, 54). How cleavage and the appear-
ance of  soluble TNFR1/2 is pathogenetically linked to 
the progression of  disease is unknown.
Several other EGFR ligands have also been linked 
to kidney fibrosis. As examples, chronic angiotensin II 
infusion in mice caused ADAM17 cleavage of  TGFα 
and sustained EGFR activation in tubular cells and kidney fibrosis, while TGFα KO mice were protect-
ed (22). We did not find significant upregulation of  TGFα in our rather different injury models. In mice, 
transgenic overexpression of  HB-EGF in the heart or pancreas (55, 56) and of  TGFα in the lung (57) 
causes fibrosis. Involvement of  specific EGFR ligands could occur due to organ-specific expression context 
or due to a specific EGFR ligand feature, such as those we described for AREG. It is, however, possible 
that nonphysiologically regulated chronic EGFR ligand overexpression or exposure (induction by chronic 
angiotensin II infusion) causes enough sustained EGFR activation to induce fibrosis, independent of  the 
ligand in question. Of  note, ADAM17 has been shown to cleave many substrates in cell lines in vitro (58), 
raising the possibility that other ADAM17 substrates might be involved. However, based on observations 
in humans and mice, EGF ligands and TNFα and likely IL6 receptor (IL-6R) indeed represent ADAM17’s 
most important physiologically relevant substrates in vivo (16, 17, 59). Trans-signaling of  soluble IL-6R has 
been linked to crescentic glomerulonephritis (60, 61).
Our results in human tissues and urines of  patients with AKI, CKD, or urinary obstruction suggest 
that ADAM17 pathways, EGFR and TNFα, are also involved in various human fibrotic kidney diseases. 
In human biopsy studies, ADAM17 expression was found significantly upregulated in transplanted kid-
neys with interstitial fibrosis-tubular atrophy (IF-TA) (62) and in various chronic fibrotic kidney diseases, 
including diabetic nephropathy, and many forms of  glomerular disease (52). In the latter study ADAM17 
Figure 8. Soluble AREG and TNFR1 are significantly increased 
in the urine of AKI and CKD patients. The urinary levels of the 
soluble ADAM17 substrates (AREG [A], TNFR1 [B], HB-EGF [C], 
TGFα [D], Axl [F], ICAM1 [G], and KIM1 [H]) and of the ADAM10 
substrate cMET (E) were measured by ELISA in control, AKI, 
and CKD patients (n = 10; 50% of CKD patients were diabetics; 
patient demographics and details in Supplemental Table 1).  
*P < 0.05; **P < 0.01; ***P < 0.001 as determined by an 
unpaired 2-tailed Student’s t test. AREG, amphiregulin; TNFR, 
tumor necrosis factor receptor; AKI, acute kidney injury; CKD, 
chronic kidney disease; ADAM17, a disintegrin and metallopro-
tease 17; HB-EGF, heparin binding epidermal growth factor-like 
growth factor; ICAM1, intercellular adhesion molecule 1; KIM1, 
kidney injury molecule 1; cMET, met.
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expression levels in the proximal tubule correlated positively with the extent of  macrophage ingress and 
interstitial fibrosis present in the sample and correlated negatively with glomerular filtration rate (a mea-
sure of  kidney function). Taken together, these results suggest that the ADAM17 pathway is also active 
in human kidney disease, and its activity is positively correlated with functional decline. Whether AREG 
could serve as a biomarker for the progression of  CKD in AKI, CKD or other fibrotic kidney diseases will 
require further studies. Recently, the presence of  soluble EGF, an EGF ligand released by ADAM10, in the 
urine of  a mixed group of  CKD patients was found to be positively correlated with preservation of  estimat-
ed glomerular filtration rate and kidney function (41). We observed a strong decline of  EGF levels in our 
acute injury models, and they stayed low throughout injury/repair up to at least 42 days. It is possible that 
levels of  soluble EGF in the urine in general reflect tubular epithelial cell health, correlate with the number 
of  intact cells and tubules, and decline with fibrosis.
In summary, our results strongly support the notion that the ADAM17-induced pathways AREG-EG-
FR and TNFα-TNFR1/2 act together to mediate kidney fibrosis after injury and identify ADAM17 and 
its dependent pathways as possible new targets in the prevention or treatment of  human fibrotic kidney 
disease. Targeting of  the ADAM17 axis in kidney disease in humans could be tested with existing drugs for 
the specific inhibition of  EGFR or TNFα used in other human diseases, and these drugs could then possi-
bly be repurposed for applications in kidney disease. Specific contributions of  EGFR and TNFα pathways 
need to be explored further (e.g., by using specific pharmacological inhibitors, alone or in combination, and 
by creating ADAM17 substrate KOs in tubular or other kidney cells).
Methods
Animal experiments. ADAM17ex/ex have been described (17). SLC34a1-GCE mice and FoxD1-GC mice 
have been described previously (14, 29). ADAM17fl/fl (or TACEflox) mice were obtained from The Jackson 
Laboratory, strain 009597. We bred the Cre and flox lines together for 2 generations and then selected 
Figure 9. Mechanisms of injury-induced ADAM17-dependent sustained EGFR activation in proximal tubule cells. 
Injury drives upregulation of ADAM17 and of its substrates, in particular pro-AREG. Increased ADAM17 activity on 
the cell surface leads to enhanced release of soluble AREG and TNFα, which activate their respective receptors. In a 
positive feedback loop, AREG-mediated EGFR activation increases ADAM17 and AREG expression. TNFα-mediated 
TNFR activation strengthens this feedback loop further by enhancing soluble AREG release (pathway crosstalk). Both 
pathways, AREG/EGFR and TNFα/TNFR, potentiate each other in inducing profibrotic and proinflammatory cytokines 
that drive kidney fibrosis. pro-TNFα, transmembrane pro–tumor necrosis factor α; sTNFα, soluble tumor necrosis factor 
α; ADAM17, a disintegrin and metalloprotease 17; EGFR, epidermal growth factor receptor; pro-AREG, proamphiregulin; 
sAREG, soluble amphiregulin; TNFR, tumor necrosis factor receptor; MCP1, monocyte chemoattractant protein 1.
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breeders to produce the experimental genotypes ADAM17WT/WTCre+/– mice (control group) and ADAM-
17fl/flCre+/– (ADAM17 PTC-KO when using SLC34a1-GCE; stroma-KO when using FoxD1-GC). For 
induction of  the SLC34a1-driven Cre, mice were injected with 3 doses of  tamoxifen 10 mg (every other 
day), and surgery was only performed 1 week later to allow for tamoxifen washout. For all studies adult 
(8- to 12-week-old) male mice were used in accordance with the animal care and use protocol approved by 
the Institutional Animal Care and Use Committee of  Harvard Medical School.
Ischemia for 30 minutes (ADAM17ex/ex and WT littermates) or 29 minutes (ADAM17 PTC-KO 
and WT littermates) at 37°C was induced in both kidneys using the flank approach as previously report-
ed (63). Sham operations were performed with exposure of  both kidneys but without induction of  
ischemia. For inhibitor experiments 0.5 mg/kg of  ADAM17 prodomain inhibitor (28) or vehicle (0.25 
ml PBS) was injected i.p. daily.
UUO was executed as described previously (63). Briefly, after flank incision, the left ureter was tied 
off  at the level of  the lower pole with two 3.0 silk ties. Sham-operated mice underwent the same surgical 
procedure, except for the ureter ligation. Seven or 14 days following surgery, mice were sacrificed, and the 
obstructed and contralateral nonobstructed kidneys were harvested for analysis.
Renal function and histology. Serum creatinine was assessed by HPLC (64) at the O’Brien Core Center 
for Acute Kidney Injury Research (University of  Alabama School of  Medicine, Birmingham, Alabama, 
USA). BUN levels were measured using the Infinity Urea assay (Thermo Scientific) according to the man-
ufacturer’s instructions. KIM1 and NGAL were measured by using Luminex xMAP Technology, as previ-
ously described (65).
Kidney histology was examined in formalin-fixed H&E, PAS, or Masson’s trichrome–stained sections. 
The degree of  tubulointerstitial damage was scored semiquantitatively (scale 1–5) as previously described 
(66). Fibrosis severity was scored in kidney cortex at ×400 magnification using a counting grid with 144 
intersections. The number of  grid intersections overlying trichrome-positive (blue) interstitial areas was 
counted and expressed as a percentage of  all grid intersections. For this calculation, intersections that were 
in tubular lumen and glomeruli were subtracted from the total number of  grid intersections. The Masson’s 
trichrome–stained sections were also used for the scoring of  the cortical interstitial area and tubular dila-
tion. Of  note, we used representative images of  cortical areas throughout this manuscript for all immuno-
fluorescence stains shown.
Immunofluorescence staining of  the kidney was performed on paraffin or frozen sections following 
standard protocols. The primary Abs included: ADAM17 (a gift from Carl Blobel, Hospital for Special Sur-
gery, New York, New York, USA), αSMA (CY3-conjugated, Sigma-Aldrich, C6198), fibronectin (Abcam, 
ab2413), CD31 (eBioscience, 14–0311) pEGFR Y1068 (Cell Signaling Technology, 3777), pEGFR Y1173 
(R&D Systems, AF1095), and AREG (R&D Systems, BAF262). Fluorescein-LTL was from Vector Labo-
ratories. Images were analyzed using ImageJ (67).
Cell culture and treatments. Primary cultures of  kidney tubular cells from ADAM17ex/ex or WT littere-
mates were generated using established methods (68). Cells were used in experiments between days 5 and 
7 of  culture. A human proximal tubular cell line (HPTC-05; ref. 69) was also used. All tubular cells were 
maintained in DMEM/F12 medium supplemented with 10 ng/ml EGF, 0.05 mM L-ascorbic-2 phosphate, 
0.004 mg/ml dexamethasone, 1.5 mM HEPES, 1.2 mg/ml NaHCO3, and 5% FBS. Fibroblast were grown 
in DMEM with 10% FBS.
All experiments were performed using subconfluent cells that were serum deprived overnight. TNFα 
(10 ng/ml) and/or equimolar (17 pM) amounts of  the different EGFR ligands (all from R&D Systems) 
were added to the cells for different time points as noted. When inhibitors were used, cells were pretreated 
with the respective inhibitor for 30 minutes before the addition of  the ligands.
Quantitative PCR. Total RNA was isolated from either the kidneys or cultured cells using the QIAzol 
reagent (Qiagen) according to the standard protocol, and total RNA was reverse transcribed using the 
QuantiTect RT kit (Qiagen). Real-time PCR was performed with the Fast SYBR Green (Qiagen) in a 384-
well plate format using the QuantStudio 7 Flex system (Applied Biosystems). GAPDH or RPLP0 were 
used as housekeeping genes. Data were analyzed using the ΔΔCt method. Primer sequences are provided 
in Supplemental Table 2.
Protein sample preparation and Western blot. Whole kidney or cell lysates were prepared as previous-
ly described and analyzed by standard Western blot techniques. The primary antibodies used include 
ADAM17, fibronectin (Abcam, ab2413), pEGFR Y1068 (Cell Signaling Technology, 2234 and 3777), 
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pERK1/2 (Cell Signaling Technology, 9101), GAPDH (Abcam, ab181602), and tubulin (Abcam, ab7291).
ELISA. Mouse TNFα and AREG were measured in kidney lysates using ELISA kits (900-M54 
PeproTech and DY989 R&D Systems) according to the manufacturer’s instructions. Human TGFα, 
HB-EGF, AREG, TNFR1, ICAM1, Axl, and cMET were measured in human urine samples using micro-
sphere-based Luminex Technology and ELISA kits (DY239, DY259, DY262, DY225, DY720, DY154, 
DY358, respectively; all from R&D Systems). Protein levels were calculated after correction for urine cre-
atinine as described (65).
Statistics. All results are reported as the mean ±SD. Comparison of  2 groups was performed using 
an unpaired, 2-tailed t test or a Pearson correlation analysis where appropriate. Statistical analyses were 
performed using GraphPad Prism, version 6.0 (GraphPad Software Inc.). A P value of  less than 0.05 was 
considered significant.
Study approval. Use of  mice in this study was reviewed and approved by the Standing Committee on 
Animals at Harvard Medical School, in adherence to standards set in the Guide for the Care and Use of  Lab-
oratory Animals (8th edition, The National Academies Press, revised 2011). Specimens for human study 
analysis were taken from patients after informed consent. The use of  these specimens was approved by the 
IRB of  the Brigham and Women’s Hospital, in adherence to the Declaration of  Helsinki.
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